Sanction covers use of drug to increase bone mass in patients with prostate or breast cancer undergoing hormone ablation therapy. FDA has approved two new indications for Amgen’s Prolia® (denosumab) ...

The FINANCIAL — Amgen on October 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia (denosumab) for ...

Amgen and UCB are co-developing EVENITY. About Prolia® (denosumab) Prolia ® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of ...

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or ...

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...

Recommendations on use of the new dual-action anabolic agent romosozumab (Evenity, Amgen) and how to safely transition between osteoporosis agents are two of the issues addressed in the latest ...